NIH and partners to start HIV vaccine trial in Europe and America
Category: #health  By Pankaj Singh  Date: 2019-07-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

NIH and partners to start HIV vaccine trial in Europe and America
  • A unit of Janssen Pharmaceutical Companies of Johnson & Johnson would be sponsoring the Mosaico trial.
  • A complementary study involving women is also currently under process in southern Africa.

The National Institutes of Health (NIH), a biomedical research unit of the U.S. Department of Health and Human Services, and its partners recently announced their plans to commence a Phase 3 clinical trial that would test the efficacy of an investigational HIV vaccine.

Reports cite, the trial would take place across a number or clinical research sites, including Europe, South America and North America. The proposed trial has been dubbed Mosaico or HPX3002/HVTN 706 and is set to launch soon.

According to reports, Janssen Vaccines & Prevention, B.V., a unit of Janssen Pharmaceutical Companies of Johnson & Johnson, would be sponsoring the Mosaico trial. The study would enroll 3,800 HIV negative transgenders and men that are sexually active with other transgenders or/and men. Along with the U.S., other countries such as Italy, Mexico, Poland, Peru, Argentina, Spain and Brazil would also be participating in the study.

The Director of NIAID Anthony S. Fauci, M.D., stated that the organization is committed towards the creation of an effective and safe HIV vaccine that would help people that are most vulnerable to HIV across globe. Dr. Fauci further added that ensuring evaluation of such investigational vaccines among a diverse demographic is crucial for attaining the goal.

All trial participants would be offered a complete HIV prevention package and would be randomly assigned either the investigational HIV vaccine or placebo. The investigational vaccines would be administered at four separate time points over a years’ worth of time.

According to reports, the Mosaico trial would be the third HIV vaccine efficacy clinical study in progress across the world. The NIH’s National Institute of Allergy and Infectious Diseases (NIAID) would be providing funding support to the clinical trial which is expected to be open for enrollment in the U.S. by the end of the year.

Source Credits: https://www.nih.gov/news-events/news-releases/nih-partners-launch-hiv-vaccine-efficacy-trial-americas-europe



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
US buys all of the global supply of Gilead’s COVID-19 drug remdesivir
By Pankaj Singh

While top-notch companies are racing to develop a vaccine for COVID-19, it looks like the United States has secured almost all of the world’s supply of interim drug remdesivir to treat patients with COVID-19.

...

Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
Potential COVID-19 vaccine by Bharat Biotech to enter clinical trials
By Pankaj Singh

Bharat Biotech International, a leading Indian biotechnology company, has reportedly announced that its potential coronavirus vaccine, Covaxin, has received Drug Controller General of India (DCGI) approval to start hum...

Seattle Genetics reveals positive data from tisotumab vedotin trial
Seattle Genetics reveals positive data from tisotumab vedotin trial
By Pankaj Singh

Seattle Genetics, Inc., a renowned biotechnology firm that focuses on developing antibody-based cancer treatments, has recently revealed positive topline data from its Phase 2 clinical trial (innovaTV 204) assessing ti...